Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0027651 (tumor)
 685,946 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Sera from cancer patients showed lymphocyte and granulocyte cytotoxic antibodies. While lymphocytotoxic antibodies correlated with the HLA system, it was not possible to demonstrate any correlation between the granulocytotoxicity and the HLA antigens. The experiments with 2 ME reduction were consistent with the presence of IgM antibodies in the majority of positive sera tested by the lymphocytotoxic method. The discussion concerning the mechanism of formation of these antibodies was only speculative. Some relationships between tumor neoantigens and the MHC were referred, but the role played by cytotoxins in the host-defence mechanism need further clarification.
 ...
PMID:Lymphocyte and granulocyte cytotoxic antibodies in cancer patients. 54 66

A survey of family histories of malignant neoplasia in multiple sclerosis (MS) patients indicates that a positive history of cancer in near relatives is present in 44 percent of patients and 46 percent of controls. However, those MS patients having such a positive history were much more likely than others to also have a family history of MS. Contrariwise, MS patients with a positive family history of MS had a significantly higher rate of cancer in first degree relatives (71 percent) than others. There was a trend indicating less cancer in families of MS patients possessing the HLA-B7 and DW2 histocompatibility antigens.
 ...
PMID:Anamnestic studies in multiple sclerosis: a relationship between familial multiple sclerosis and neoplasia. 56 46

Peripheral blood lymphocytes from 15 patients with hypernephroma were stimulated with partially purified tumor plasma membranes to incorporate [3H]thymidine. Kidney tumor and normal kidney membranes were adjusted to antigenic equivalence as determined by their ability to inhibit in the HLA 51Cr microcytotoxicity assay. Membranes from control "normal" kidney adjacent to the tumor stimulated less than did the tumor. Six of eight patients responded to autologous tumor (p less than 0.05). One patient responded to allogeneic tumor of the same histological type. The importance of statistical analyses of tumor membrane lymphocyte stimulation data is discussed in relation to the assay system. Sequential studies suggest that this assay may be useful as a guideline for the monitoring of current therapeutic regimens and future immunotherapy. The results of this assay are discussed in relation to other in vitro tumor lymphocyte stimulation assays. The limitations of this assay appear to be two: (a) it can be used only in large tumor systems where there is adequate tissue for analysis and controls; (b) it may detect nontumorous antigens or nonspecific stimulators in allogeneic studies. Further studies are needed to correlate the blastogenic response with the patient's prognosis.
 ...
PMID:Tumor membrane lymphocyte stimulation assay in patients with renal cell carcinoma. 64 59

A tumor plasma membrane LSA has been developed to measure cell-mediated immunity in patients with renal cell carcinoma. In this assay system, plasma membranes are adjusted to antigenic equivalence with the use of HLA as a plasma membrane marker. Fifteen patients were studied; 6 of 8 had a significant response to autologous tumor (P less than 0.05). Of 7 patients studied with allogeneic tumor, only 1 was responsive. Various parameters of the tumor membrane LSA are discussed, including dose response, kinetics, and method of data presentation.
 ...
PMID:Renal cell carcinoma: tumor membrane lymphocyte stimulation assay. 74 68

Sera from patients with various types of central nervous system tumors display antibodies reactive in serologic assays with cells and extracts derived from human brain neoplasms. Soluble antigens extracted and purified from surgical specimens of human meningiomas (MSA) were used to test for precipitating antibodies in sera from patients with various histologic types of brain tumors, non-neural solid tumors and from normal donors. Blind studies by immunodiffusion (ID) showed that 63% (15/24) of meningioma patients, 53% (9/17) of glioma patients and 17% (5/29) of patients with various other brain neoplasms had antibodies that reacted with two of three meningioma-associated antigens. Sera from normal donors and patients with non-neural solid neoplasms reacted to a limited extent (7/118) with another of these tumor-associated antigens. Cross-reaction and absorption studies revealed that the three meningioma-associated antigens were detecting different antibodies. None of the antigens was related to HLA antigens or to the human non-neurotropic viruses used in our assays.
 ...
PMID:Human meningioma antigens. 80 46

Point mutations in ras genes resulting in substitutions of amino acid Gly in positions 12 and 13, and Gln in position 61 of the ras gene product p21, are commonly found in human tumors. Peptides derived from aberrant p21 may elicit a tumor specific T cell response, provided that these peptides can bind to HLA molecules of the tumor and the patient has T cells able to recognize the corresponding peptide-HLA complex. Here we report that CD4+ T cells of memory type (CD45RO+) from a patient with a follicular thyroid carcinoma respond against a synthetic peptide derived from aberrant p21 ras having a Gln-->Leu substitution at position 61. Such responses were not observed when T cells from healthy volunteers or cancer patients where this mutation does not usually occur were stimulated with this peptide. The responding T cells did not cross-react with the corresponding peptide derived from native p21 ras nor did they recognize peptides carrying other substitutions in position 61. T cells clones were generated which recognized this Leu61 peptide when presented by HLA-DQ8 molecules. These T cell clones also recognized the corresponding intact p21 ras protein. By using several different synthetic peptides, a peptide with optimal stimulatory capacity was defined. Performing polymerase chain reaction and oligonucleotide probing we were, however, not able to detect the p21 ras gene encoding the Gln-->Leu substitution in DNA from tumor biopsies from the patient. This may indicate that tumor cells harboring the mutation leading to the Gln-->Leu substitution had been eliminated and that tumor progression was due to cells that had deleted the mutated ras gene. The finding that ras derived peptides and recombinant mutated p21 ras are immunogenic in man may form the basis for the development of cancer immunotherapy based on synthetic oncogene derived peptides.
 ...
PMID:Memory T cells of a patient with follicular thyroid carcinoma recognize peptides derived from mutated p21 ras (Gln-->Leu61). 128 32

MHC class I antigens participate in the immune response by presenting peptides to CD8+ cytotoxic T cells. Decreased expression of these antigens in tumor cells may contribute to an evasion of immune system and consequently to enhanced tumor growth. However, not all tumors expressing low levels of HLA antigens show increased malignancy, probably as a result of the differential activity of the oncogenes involved in malignant transformation. The ras family of cellular oncogenes is one of the most frequently detected families of transformation-inducing genes in human solid tumors. The aim of this work is to study the expression of MHC antigens and the ras oncogene product, p21ras, in 60 primary breast tumors in order to define its clinical significance in tumor progression. HLA antigen expression and p21ras levels were measured on breast tumors using immunohistochemistry methods and enzymoimmunoassay, respectively. The results demonstrate that more invasive tumors have both a decreased expression of HLA class I antigens and higher levels of p21ras protein expression than less aggressive tumors. These findings indicate that the capacity of breast cancers to grow and metastasize is related to low levels of MHC class I antigens and enhanced p21ras expression, thus supporting the involvement of MHC and ras oncogenes in breast tumor malignancy.
 ...
PMID:MHC class I antigen expression is inversely related with tumor malignancy and ras oncogene product (p21ras) levels in human breast tumors. 129 32

The loss of HLA antigens by neoplastic cells is considered important for tumor growth and metastasis, since it may allow tumors to escape immune surveillance. We studied the expression of HLA class I and II antigens in the colons of 10 patients with familial adenomatous polyposis (FAP), a condition which leads inevitably to colorectal cancer. Expression of HLA class antigens was studied by immunohistochemistry in (a) adenomas from patients with FAP, (b) histologically normal mucosa distant from the adenomas, and (c) histologically normal colonic mucosa from normal subjects. The expression of HLA class I and II antigens was decreased in histologically normal mucosa from FAP patients compared to normal controls. Adenomas showed a similar but quantitatively more pronounced reduction (or loss) of HLA antigen expression. The reduction of HLA expression in adenomas was comparable to that observed in sporadic colon carcinomas. This generalized suppression of HLA gene expression in the colon of FAP patients, which precedes the onset of overt histological manifestations of neoplasia, may be an important early event in colon carcinogenesis.
 ...
PMID:Loss of colonic HLA antigens in familial adenomatous polyposis. 131 51

The presence of HPV DNA in the genital tract and the genotype of the infecting HPV are now widely employed as biochemical markers in epidemiological studies of cervical cancer. Additional HPV markers could be utilized in future investigations. The amount of HPV DNA is likely to be higher in case specimens than in control specimens; viral genome would be integrated frequently in cases but almost never in controls; and early region transcripts may be relatively more abundant in cases than in controls. When valid serological markers for past HPV infection become available (very likely, antibodies to HPV capsid proteins), they will be useful to estimate lifetime exposure to HPVs. Serological markers for HPV-associated neoplasia (very likely, antibodies to early proteins) may prove useful for surveillance and have prognostic value. A serological marker capable of detecting past herpes simplex virus 2 infection would permit an analysis of the role of this virus in cervical cancer, either as an independent risk factor or in interaction with HPVs. Other possible biomarkers include activation of oncogenes and inactivation of tumour-suppressor genes, assays for serum micronutrients, and analysis of leukocytes for HLA antigens; these should provide insights into the sequence of events that lead to cervical cancer and help to explain the geographic distribution of the disease.
 ...
PMID:Human papillomaviruses and other biological markers in cervical cancer. 133 Sep 11

The Eaton-Lambert syndrome is a clinical and electrophysiological entity, which affects less than 3% of patients with a small cell cancer. In the majority of cases the syndrome is present before the discovery of cancer. The diagnosis is primarily suggested by proximal muscle fatiquibility in the lower limbs. The confirmation of the diagnosis is carried out by an electromyography. The occurrence of non-para neoplastic cases are frequently associated with disorders of immunity (Auto-immune Disease, and various auto-antibodies) in the groups HLA B8 and DR3. The efficacy of immunosuppressants has led to a search for an auto-immune mechanism as the basis for this myasthenic type syndrome. The demonstration in recent years of anti-calcium channel antibodies at the origin of the pre-synaptic junctional block has confirmed this hypothesis. The demonstration of the auto-immune character of this para-neoplastic syndrome has led to better understanding of the host tumour relationship from an immunopathological stand point.
 ...
PMID:[The Lambert-Eaton syndrome]. 133 48


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>